Immunai has partnered with the Parker Institute for Cancer Immunotherapy to generate a large-scale, clinically annotated single-cell gene expression dataset from over 1,000 cancer patients receiving checkpoint inhibitor therapies. This homogeneous dataset will fuel training of Immunai’s AI models of the human immune system, aiming to accelerate immune-oncology drug discovery and precision medicine. The partnership represents a significant step in leveraging AI with high-resolution single-cell data for improved therapeutic development.